The purpose of the trial is to determine whether the new drug works at least as well as the existing treatment in preserving or improving vision. Vision will be assessed using a standard test called Best-Corrected Visual Acuity, which measures how many letters a person can read on an eye chart, reported in ETDRS letters.

Participants will receive a series of eye injections over roughly one year, with regular visits to check eye health, vision scores, and any side effects. The study is designed so that neither the participants nor the doctors know which medication is being given at each visit.

Participants in the study will receive either the HLX10 treatment or a placebo, alongside the standard chemotherapy and radiotherapy. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the HLX10 or the placebo. This helps ensure that the results are unbiased. The study will take place over a period of time, with regular monitoring to assess the treatment’s impact on the cancer and any side effects experienced by the participants.

The main goal is to see if the combination of HLX10 with chemotherapy and radiotherapy can improve overall survival rates for patients with LS-SCLC. Secondary goals include measuring progression-free survival, which is the length of time during and after treatment that a patient lives with the disease without it getting worse, and the objective response rate, which is the proportion of patients whose cancer shrinks or disappears after treatment. The study will also monitor the quality of life of participants and any adverse events that occur during the trial.

Adults and adolescents in the study are assigned by chance to receive either GB-0895 or placebo, and neither the participants nor the study team knows which one is given during the study. Treatment is given over about 52 weeks, with regular study visits during that time. The study looks at how asthma changes over the year, including flare-ups, breathing, asthma symptoms, and daily life with asthma.

Some medical terms used in the study include exacerbations, which means asthma flare-ups that are bad enough to need steroid medicine or a hospital or emergency room visit, and forced expiratory volume in 1 second (FEV1), which is the amount of air that can be blown out in one second. The study also uses systemic corticosteroids, which are steroid medicines that work throughout the body.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

In the study, people are randomly assigned to receive either the new treatment combination or the standard treatment combination. The medicines are given as intravenous infusion, which means they are delivered slowly through a vein. Treatment is given in cycles over time, with regular visits for infusions and checks by the study team. The study will look at how long people live and will also follow symptoms and side effects, including breathing problems, chest pain, cough, and treatment-related reactions such as CRS and ICANS. CRS, or cytokine release syndrome, is a strong immune reaction that can cause fever and other symptoms. ICANS, or immune effector cell-associated neurotoxicity syndrome, is a brain and nerve problem that can affect thinking, speech, or alertness.

The study is a long-term extension, which means it follows people over a longer period after earlier treatment. During the trial, the medicine is taken by mouth and participants are watched over time for side effects and other health changes. Regular checkups and laboratory tests are used to follow general health, joint symptoms, and skin symptoms while treatment continues.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The purpose of this research is to determine how well IMVT-1402 works compared to placebo in treating adults with Graves’ Disease. The study examines the medication’s effects on thyroid hormone levels and the need for standard thyroid medications over a 26-week period.

During the study, participants will receive either IMVT-1402 injections or placebo. The medication will be given as a subcutaneous injection, which means it is administered under the skin. The maximum daily dose of the study medication can be up to 600 milligrams. The study will monitor how the treatment affects thyroid hormone levels and overall thyroid function throughout the treatment period.

The purpose of this research is to evaluate how well different doses of Rocatinlimab work compared to placebo in reducing itching in people with Prurigo Nodularis. The medication will be given as a subcutaneous injection (an injection under the skin). The study will last for 52 weeks, during which participants will receive either Rocatinlimab or placebo.

Throughout the study, participants will need to keep a daily record of their symptoms, including itching intensity and skin pain. Doctors will regularly examine the skin nodules and monitor how the treatment affects participants’ quality of life and sleep. The study will also track any side effects that may occur during the treatment period.

The aim is to see if adding Panzyga can lower the chance of a major infection or death in this vulnerable group. Participants will receive the assigned infusion once every few weeks for several months, and they will be checked regularly by doctors for any signs of infection, side effects, or changes in health. The study is set up so that neither the participants nor the doctors know which infusion is being given, to keep the comparison fair.

Throughout the trial, any infection that occurs will be recorded, and an independent group of experts will decide whether it meets the definition of a major infection. Safety will also be monitored by looking at reported side effects and routine lab tests. The information gathered will help determine whether the treatment is safe and effective for preventing serious infections in people with weak immune systems due to their underlying disease and therapy.